OVERVIEW

Immunotherapies

Immunotherapies are a type of 'biological therapy' that influence the immune system and help fight disease. They can stimulate the immune system to detect and and target cancer cells, or may suppress an over-active immune system for treatment of autoimmune disease. These immunotherapies can be highly effective against various diseases, and may be in the form of antibodies or vaccines. 

Immunotherapy research at TRI includes:

  • UQ Professor Riccardo Dolcetti's group is currently exploring the therapeutic potential of a novel cancer vaccine, and is exploring strategies to overcome resistance to cancer immunotherapies.
  • Associate Professor Kristen Radford leads the Mater Research Cancer Immunotherapies Research Team, with a focus on human dendritic cell biology and translating findings into health benefits. This research group has developed novel research tools, including humanised mice models, which are highly sought after in the biomedical world and continues to lead in this area.
  • UQ Professor Nikolas Haass is investigating ways to mark melanoma cells for detection by the immune system, to enhance the anti-tumour response. 

In addition, the following companies based at TRI are achieving translational success and progressing their immunotherapy products through clinical trials:

Admedus Immunotherapies is a global medical technologies company based at TRI that is currently involved in demonstrating clinical proof of concept for a vaccine to treat HPV-associated head and neck cancers. Check out the TRIangle Video Series: Episode 2 - Immunotherapies for Head and Neck Cancer to learn more. 

Dendright is a clinical-stage biopharmaceutical company based at TRI developing an immunotherapy for rheumatoid arthritis. Founded by UQ Professor Ranjeny Thomas, the team at Dendright have developed and patented a liposome vaccine strategy to induce antigen-specific tolerance in rheumatoid arthritis.

To find out more about their technology, watch this video

 

Related News

Key Researchers
 
Riccardo Dolcetti
Ian Frazer
Antje Blumenthal
Graham Robert Leggatt
James William Wells
Kristen Radford
Nikolas Haass
Show More ...
Article
Clinician-researcher focuses on patients with rare lymphoma Haematologist, Dr Colm Keane, has a clear focus on improving patient outcomes through his lymphoma research program at the Translational...Read more
Article
Awakening the immune system to fight diseases Scientists at The Translational Research Institute (TRI) are harnessing the body’s front-line immune cells to fight cancer, with potential new...Read more
Article
Reduced immune infiltration into nodes associated with poor outcomes in follicular lymphoma Research published today in the highly prestigious Journal of Clinical Oncology by Mater Research CEO and...Read more
Article
Can a patient’s own immune cells be modified to cure a rare and deadly type of lymphoma? Professor Maher Gandhi, CEO of Mater Research and Director of Mater Research Institute-UQ, is leading a...Read more
Article
A global front runner in cervical cancer prevention: Australia on track to eliminate cervical cancer by 2035 New research published today has revealed that cervical cancer may be eliminated as a...Read more
TRANSLATING INNOVATION PROGRAMS Translating Innovation Programs are a collection of related projects based at TRI which involve collaboration across institutes, technologies and disciplines, united...Read more

Rheumatoid arthritis vaccine

Rheumatoid Arthritis vaccine 

Professor Ranjeny Thomas has led the development and Phase I clinical trial of a first-in-class immunotherapy for the treatment of Rheumatoid Arthritis (RA).